Marine pyrrolocarbazoles and analogues: Synthesis and kinase inhibition

Marine Drugs

Volumn 7, Issue 4, 2009, Pages 754-786

  Deslandes, Sébastien ^a   Chassaing, Stefan ^a   Delfourne, Evelyne ^a  

^a Universite Toulouse III Paul Sabatier   (France)

Author keywords

Granulatimide; Indolocarbazole; Isogranulatimide; Kinase inhibitor; Pyrrolocarbazole

Indexed keywords

10 METHYLGRANULATIMIDE; 10,17 DIMETHYLGRANULATIMIDE; 7 HYDROXYSTAUROSPORINE; ALKALOID DERIVATIVE; CARBAZOLE DERIVATIVE; CHECKPOINT 1 KINASE; CHECKPOINT 2 KINASE; DIDEMNIMIDE A; DIDEMNIMIDE B; DIDEMNIMIDE C; DIDEMNIMIDE D; DIDEMNIMIDE E; GLYCOGEN SYNTHASE KINASE 3BETA; GRANULATIMIDE; ISOGRANULATIMIDE; ISOGRANULATIMIDE A; ISOGRANULATIMIDE B; ISOGRANULATIMIDE C; NAPHTHALENE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHENYLPYRROLOCARBAZOLE; PHOSPHOTRANSFERASE; PROTEIN P53; PYRIDINE DERIVATIVE; PYRROLOCARBAZOLE; QUINONE DERIVATIVE; REBECCAMYCIN; RUTHENIUM COMPLEX; STAUROSPORINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BROMINATION; CATALYSIS; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; DIELS ALDER REACTION; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FEEDBACK SYSTEM; GENE MUTATION; GLYCOGEN METABOLISM; HUMAN; IC 50; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR;

EID: 75149126421     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md7040754     Document Type: Review

References (81)

1. Manning, G.; Whyte, D.B.; Martinez, R.; Hunter, Sudarsanam, T.S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
2. Garcia-Echeverria, C.; Traxler, P.; Evans, D.B. ATP site-directed competitive and irreversible inhibitors of protein kinases. Med. Res. Rev. 2000, 20, 28-57.
3. Sielecki, T.M.; Boylan, J.F.; Benfield, P.A.; Trainor, G.L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 2000, 43, 1-18.
4. Traxler, P.; Bold, G.; Buchdunger, E.; Caravatti, G.; Furet, P.; Manley, P.; O'Reilly, T.; Wood, J.; Zimmermann, J. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 2001, 21, 499-512.
5. Toogood, P.L. Cyclin-dependent kinase inhibitors for treating cancer. Chem. Rev. 2001, 101, 2541-2572.
6. Bridges, A.J. Chemical inhibitors of protein kinases. Chem. Rev. 2001, 101, 2541-2572.
7. Scapin, G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. 2001, 7, 601-611.
8. Sridhar, R.; Hanson-Painton, O.; Cooper, D.R. Protein kinase as therapeutic targets. Pharm. Res. 2000, 17, 1345-135
9. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9, 28-39.
10. Berlinck, R.G.S.; Britton, R.; Piers, E.; Lim, L.; Roberge, M.; Moreira da Rocha, R.; Andersen, R.J. Granulatimide and isogranulatimide, aromatic alkaloids with G2 checkpoint inhibition activity isolated from the brazilian ascidian Didemnun granulatum: structure elucidation and synthesis. J. Org. Chem. 1998, 63, 9850-9856.
11. Jiang, X.; Zhao, B.; Britton, R.; Lim, L.Y.; Leong, D.; Sanghera, J.S.; Zhou, B.B.S.; Piers, E.; Andersen, R.J.; Roberge, M. Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide. Mol. Cancer Ther. 2004, 3, 1221-1227.
12. Zhao, S.; Weng, Y.-C.; Yuan, S.-S. F.; Lin, Y.-T; Hsu, H.-C.; Lin, S.-C. J.; Gerbino, E.; Song, M.-H.; Zdzienicka, P. Functional link between ataxia-telangiectasia and nijmegen breakage syndrome gene products. Nature, 2000, 405, 473-476.
13. Curman, D.; Cinel, B.; Williams, D.E.; Rundle, N.; Block, W.D.; Goodarzi, A.A.; Hutchins, J.R.; Clarke, P.R.; Zhou, B.-B.; Lees-Miller, S.P.; Andersen, R.J.; Roberge, M. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J. Biol. Chem. 2001, 276, 17914-17919.
14. Zhao, B.; Bower, M.J.; McDevitt, P.J.; Zhao, H.; Davies, S.T.; Johanson, K.O.; Green, S.M.; Concha, N.O.; Zhou, B.B.S. Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem. 2002, 277, 46609-46615.
15. Hénon, H.; Conchon, E.; Hugon, B.; Messaoudi, S.; Golsteyn, R.M. Prudhomme. Pyrrolocarbazoles as checkpoint 1 kinase inhibitors. Anti-Cancer Agents Med. Chem. 2008, 8, 577-597.
16. Roberge, M.; Berlinck, R.G.S.; Xu, L.; Anderson, H.J.; Lim, L.Y.; Curman, D.; Stringer, C.M.; Friend, S.H.; Davies, P.; Vincent, I.; Haggarty, S.J.; Kelly, M.T.; Britton, R.; Piers, E.; Andersen, R.J. High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. J. Cancer Res. 1998, 58, 5701-5706.
17. Vervoort, H.C.; Fenical, W.; Keifer, P.A. A cyclised didemnimide alkaloid from the Caribbean ascidian Didemnum conchyliatum. J. Nat. Prod. 1999, 62, 389-391.
18. Vervoort, H.C.; Richards-Gross, S.E.; Fenical, W. Didemnimides A-D: Novel predator-deterrent alkaloids from the carribean mangrove ascidian Didemnum conchyliatum. J. Org. Chem. 1997, 62, 1486-1490.
19. Britton, R.; de Oliveiras, J.H.H.L.; Andersen, R.J.; Berlinck, R.G.S. Granulatimide and 6-bromogranulatimide, minor alkaloids of the brazilian ascidian Didemnum granulatum. J. Nat. Prod. 2001, 64, 254-255.
20. Seleghim, M.H.R.; De Lira, S.P.; Campana, P.T.; Berlink, R.G.S.; Custodio, M.R. Localization of granulatimide alkaloids in the tissues of the ascidian Didemnum granulatum. Ma. Biol. 2007, 150, 967-975.
21. Piers, E.; Britton, R.; Andersen, R.J. Improved synthesis of isogranulatimide, a G2 checkpoint inhibitor synthesis of didemnimide C, isodidemnimide A, neodidemnimide A, 17-methylgranulatimide, and isogranulatimide A-C. J. Org. Chem. 2000, 65, 530-535.
22. Yoshida, T.; Nishiyachi, M.; Nakashima, N.; Murase, M.; Kotani, E. New synthetic route to granulatimide and its structural analogues. Chem. Pharm. Bull. 2002, 50, 872-876.
23. Yoshida, T.; Nishiyachi, M.; Nakashima, N.; Murase, M.; Kotani, E. Synthesis of granulatimide positional analogues. Chem. Pharm. Bull. 2003, 51, 209-214.
24. Hugon, B.; Pfeiffer, B.; Renard, P.; Prudhomme, M. Synthesis of isogranulatimides A and B analogues possessing a 7-azaindole unit instead of an indole moiety. Tetrahedron Lett. 2003, 44, 4607-4611.
25. Hugon, B.; Anizon, F.; Bailly, C.; Golsteyn, R. M.; Pierré, A.; Léonce, S.; Hickman, J.; Pfeiffer, B.; Prudhomme, M. Synthesis and biological activities of isogranulatimide analogues. Bioorg. Med. Chem. 2007, 15, 5965-5980.
26. Hénon, H.; Messaoudi, S.; Anizon, F.; Aboab, B.; Kucharczyk, N.; Léonce, S.; Golsteyn, R.M.; Pfeiffer, B.; Prudhomme, M. Bis-imide granulatimide analogues as potent checkpoint 1 kinase inhibitors. Eur. J. Pharm. 2007, 554, 106-112.
27. Conchon, E.; Anizon, F.; Aboab, B.; Prudhomme, M. Synthesis and biological activities of new checkpoint kinase 1 inhibitors structurally related to granulatimide. J. Med. Chem. 2007, 50, 4669-4680.
28. Conchon, E.; Anizon, F.; Aboab, B.; Golsteyn, R.M.; Léonce, S.; Pfeiffer, B.; Prudhomme, M. Synthesis, checkpoint kinase 1 inhibitory properties and in vitro antiproliferative activities of new pyrrolocarbazoles. Bioorg. Med. Chem. 2008, 16, 4419-4430.
29. Tao, M.; Park, C.H.; Bihovsky, R.; Wells, G.J.; Husten, J.; Ator, M.A.; Hudkins, R.L. Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 938-942.
30. Wells, G.J.; Bihovsky, R.; Hudkins, R.L.; Ator, M.A.; Husten, J. Synthesis and structure-activity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett. 2006, 16, 1151-1155.
31. Sanchez-Martinez, C.; Shih, C.; Faul, M.M.; Zhu, G.; Paal, M.; Somoza, C.; Li, T.; Kumrich, C. A.; Winneroski, L.L.; Xun, Z.; Brooks, H.B.; Patel, B.K.R.; Schultz, R.M.; DeHan, T.B.; Spencer, C.D.; Watkins, S.A.; Considine, E.; Dempsey, J.A.; Ogg, C.A.; Campbell, R.M.; Anderson, B.A.; Wagner, J. Aryl[a]pyrrolo[3,4-c]carbazoles as selective Cyclyn D1-CDK4 inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 3835-3839.
32. Faul, M.M.; Winneroski, L.L.; Kumrich, C.A. A new efficient method for the synthesis of bisindolylmaleimides. J. Org. Chem. 1998, 63, 6053-6058.
33. Faul, M.M.; Winneroski, L.L.; Krumrich, C.A. A new one step synthesis of maleimides by condensation of glyoxylate esters with acetamides. Tetrahedron Lett. 1999, 40, 1109-1112.
34. Zhu, G.; Conner, S.; Zhou, X.; Shih, C.; Brooks, H.B.; Considine, E.; Dempsey, J.A.; Ogg, C.; Patel, B.; Schultz, R.M.; Spencer, C.D.; Teicher, B.; Watkins, S.A. Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo[3,4-c]carbazoles as cyclin D1/CDK4 inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1231-1235.
35. Routier, S.; Peixoto, P.; Mérour, J.Y.; Coudert, G.; Dias, N.; Bailly, C.; Pierré, A.; Léonce, S.; Caignard, D.H. Synthesis and biological evaluation of novel naphtocarbazoles as potential anticancer agents. J. Med. Chem. 2005, 48, 1401-1413.
36. Routier, S.; Mérour, J.-Y.; Dias, N.; Lansiaux, A.; Bailly, C.; Lozach, O.; Meijer, L. Synthesis and biological evaluation of novel phenylcarbazoles as potential anticancer agents. J. Med. Chem. 2006, 49, 789-799.
37. Bregman, H.; Williams, D.S.; Atila, G.E.; Carroll, P.J.; Meggers, E. An organometallic inhibitor for glycogen synthase kinase 3. J. Am. Chem. Soc. 2004, 126, 13594-13595.
38. Woodgett, J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 25, 923-929.
39. Williams, D.S.; Atilla, G.E.; Bregman, H.; Arzoumanian, A.; Klein, P.S.; Meggers, E. Switching on a signalling pathway with an organoruthenium complex. Angew. Chem. Int. Ed. 2005, 44, 1984-1987.
40. Bregman, H.; Williams, D.S.; Meggers, W. Pyrido[2,3-a]pyrrolo[3,4-c] carbazole-5,7(6H)-diones: synthesis, cyclometalation and protein kinase inhibition. Synthesis 2005, 9, 1521-1527.
41. Atilla-Gokcumen, G.E.; Williams, D.S.; Bregman, H.; Pagano, N.; Meggers, E. Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3. ChemBioChem 2006, 7, 1443-1450.
42. Bregman, H.; Meggers, E. Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety. Org. Lett. 2006, 24, 5465-5468.
43. Bregman, H.; Carroll, P.J.; Meggers, E. Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. J. Am. Chem. Soc. 2006, 128, 877-884.
44. Atilla-Gokcumen, G.E.; Pagano, N.; Streu, C.; Maksimoska, J.; Filippakopoulos, P.; Knapp, S.; Meggers, E. Extremely tigh binding of a ruthenium complex to glycogen synthase kinase 3. ChemBioChem 2008, 9, 2933-2936.
45. Anand, R.; Maksimoska, J.; Pagano, N.; Wong, E.Y.; Gimotty, P.A.; Diamond, S.L.; Meggers, E.; Marmorstein, R. Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor. J. Med. Chem. 2009, 52, 1602-1611.
46. Nettleton, D.E.; Doyle, T.W.; Kirshnan, B.; Matsumoto, G.K.; Clardy, J. Isolation and structure of rebeccamycin a new antitumor antibiotic from nocardia aerocoligenes. Tetrahedron Lett. 1985, 25, 4011-4014.
47. Omura, S.; Iwai, Y.; Hirano, A.; Nakagawa, A.; Awaya, J.; Tsuchiva, H.; Takahashi, Y.; Masuma, R. A new alkaloid AM-2282 of Streptomyces origin: Taxonomy, fermentation and preliminary characterization. J. Antibiot. 1977, 30, 275-282.
48. Omura, S.; Sasaki, Y.; Iwai, Y.; Takeshima, H. Staurosporine, a potentially important gift from a microorganism. J. Antibiot. 1995, 48, 535-548.
49. Rodrigues Pereira, E.; Belin, L.; Sancelme, M.; Prudhomme, M.; Ollier, M.; Rapp, D.; Sevère, D.; Riou, J.F.; Fabbro, D.; Meyer, T. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J. Med. Chem. 1996, 39, 4471-4477.
50. Gray, N.; Détivaud, L.; Doerig, C.; Meijer, L. ATP-Site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6, 859-875.
51. Goeke, K.; Hoehn, P.; Ghisalba, O. Production of the staurosporine aglycon K-252C with a blocked mutant of the staurosporine producer strain Streptomyces longisporoflavus and by biotransformation of staurosporine with Streptomyces mediddicm ATCC 13279. J. Antibiot. 1995, 48, 428-430.
52. Rialet, V.; Meijer, L. A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2/cyclin Bcd13, affinity immobilized on p13suc1-coated microtitration plates. Anticancer Res. 1991, 11, 1581.
53. Al-Obeidi, F.A.; Lam, K.S. Development of inhibitors for protein tyrosine kinases. Oncogene 2000, 19, 5690-5702.
54. Prudhomme, M. Biological targets of antitumor indolocarbazoles bearing a sugar moiety. Curr. Med. Chem. Anticancer Agents 2004, 4, 509-521.
55. Prudhomme, M. Staurosporine and structurally related indolocarbazoles as antitumor agents. In Anticancer Agents from Natural Products; Cragg, G.M., Gordon, M., Kingston, D.G.I., Newman, D.J., Eds.; CRC Press: Boca Raton, FL, USA, 2005; pp. 499-517.
56. Hosoya, T.; Yamamoto, Y.; Uehara, Y.; Hayashi, M.; Komiyama, K.; Ishibashi, M. New cytotoxic bisindole alkaloids with protein tyrosine kinase inhibitory activity from a myxomycete Lycogala epidendrum. Bioorg. Med. Chem. Lett. 2005, 15, 2776-2780.
57. Engler, T.A.; Furnee, K.; Malhotra, S.; Sanchez-Martinez, C.; Shih, C.; Xie, W.; Zhu, G.; Zhou, X.; Conner, S.; Faul, M.M.; Sullivan, K.A.; Kolis, S.P.; Brooks, H.B.; Patel, B.; Schultz, R.M.; DeHan, T.B.; Kirmani, K.; Spencer, C.D.; Watkins, S.A.; Considine, E.L.; Dempsey, J.A.; Ogg, C.A.; Stamm, N.B.; Anderson, B.D.; Campbell, R.M.. Vasudevan, V.; Lytle, M.L. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles. Bioorg. Med. Chem. Lett. 2003, 13, 2261-2267.
58. Faul, M.M.; Engler, T.A.; Sullivan, K.A.; Grutsch, J.L.; Clayton, M.T.; Martinelli, M.J.; Pawlak, J.M.; LeTourneau, M.; Coffey, D.S.; Pedersen, S.W.; Kolis, S.P.; Furness, K.; Malhotra, S.; Alawar, R.S.; Ray, J.E. Synthetic approaches to indolo[6,7-α]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors. J. Org. Chem. 2004, 69, 2967-2975.
59. Zhu, G.; Conner, S.E.; Zhou, X.; Chan, H.K.; Shih, C.; Engler, T.A.; Al-awar, R.S.; Brooks, H.B.; Watkins, S.A.; Spencer, C.D.; Schultz, R.M.; Dempsey, J.A.; Considine, E.L.; Patel, B.R.; Ogg, C.A.; Vasudevan, V.; Lytle, M.L. Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependant kinase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3057-3061.
60. Al-awar, R.S.; Ray, J.E.; Hecker, K.A.; Huang, J.; Waid, P.P.; Shih, C.; Brooks, H.B.; Spencer, C.D.; Watkins, S.A.; Patel, B.R.; Stamm, N.B.; Ogg, C.A.; Shultz, R.M.; Considine, E.L.; Faul, M.M.; Sullivan, K.A.; Kolis, S.P.; Grutsch, J.L.; Joseph, S. 1,7-Annulated indolocarbazoles as cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3217-3220.
61. Moreau, P.; Gaillard, N.; Marminon, C.; Anizon, F.; Dias, N.; Baldeyrou, B.; Bailly, C.; Pierré, A.; Hickman, J.; Pfeiffer, B.; Renard, P.; Prudhomme, M. Semi-synthesis, topoisomerase I and kinases inhibitory properties and antiproliferative activities of new rebeccamycin derivatives. Bioorg. Med. Chem. 2003, 11, 4871-4879.
62. Balasubramanian, B.N.; St. Laurent, D.R.; Saulnier, M.G.; Long, B.H.; Bachand, C.; Beaulieu, F.; Clarke, W.; Deshpande, M.; Eummer, J.; Fairchild, C.R.; Frennesson, D.B.; Kramer, R.; Lee, F. Y.; Mahler, M.; Martel, A.; Naidu, B.N.; Rose, W.C.; Russell, J.; Ruediger, E.; Solomon, C.; Stoffan, K.M.; Wong, H.; Zimmermann, K.; Vyas, D.M. Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13H-benzo[b]-thienyl[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H) -dione (BMS-251873) with curative antitumor activity against xenograft tumor model. J. Med. Chem. 2004, 47, 1609-1612.
63. Saulnier, M.G.; Balasubramanian, B.N.; Long, B.H.; Frennesson, D.B.; Ruediger, E.; Zimmermann, K.; Eummer, J.T.; St. Laurent, D.R.; Stoffan, K.M.; Naidu, B.N.; Mahler, M.; Beaulieu, F.; Bachand, C.; Lee, F.Y.; Fairchild, C.R.; Stadnick, L.K.; Rose, W.C.; Solomon, C.; Wong, H.; Martel, A.; Wright, J.J.; Kramer, R.; Langley, D.R.; Vyas, D.M. Discovery of a fluoroindolo[2,3-α] carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11. J. Med. Chem. 2005, 48, 2258-2261.
64. Anizon, F.; Moreau, P.; Sancelme, M.; Laine, W.; Bailly, C.; Prudhomme, M. Rebeccamycin analogues bearing amine substituents or other groups on the sugar moiety. Bioorg. Med. Chem. 2003, 11, 3709-3722.
65. Faul, M.M.; Sullivan, K.A.; Grutsch, J.L.; Winneroski, L.L.; Shih, C.; Sanchez-Martinez, C.; Cooper, J.T. Synthesis of indolo[2,3-a]carbazole glycoside analogs of rebeccamycin: inhibitors of cyclin D1-CDK4. Tetrahedron Lett. 2004, 45, 1095-1098.
66. Zhang, G.; Shen, J.; Cheng, H.; Fang, L.; Luo, S.; Muller, M.T.; Lee, G.E.; Wei, L.; Du, Y.; Sun, D.; Wang, P.G. Synthesis and biological activities of rebeccamycin analogues with uncommon sugars. J. Med. Chem. 2005, 48, 2600-2611.
67. Roy, S.; Eastman, A.; Gribble, G.W. Synthesis of 7-keto-Gö6976 (ICP-103). Synth. Commun. 2005, 35, 595-601.
68. Roy, S.; Eastman, A.; Gribble, G.W. Synthesis of N-alkyl substituted bioactive indolocarbazoles related to Gö6979. Tetrahedron 2006, 62, 7838-7845.
69. Faul, M.M.; Winneroski, L.L.; Kumrich, C.A. A new efficient method for the synthesis of bisindolylmaleimides. J. Org. Chem. 1998, 63, 6053-6058. (b)
70. Faul, M.M.; Winneroski, L.L.; Krumrich, C.A. A new one step synthesis of maleimides by condensation of glyoxylate esters with acetamides. Tetrahedron Lett. 1999, 40, 1109-1112.
71. Roy, S.; Eastman, A.; Gribble, G.W. Synthesis of bisindolylmaleimides related to GF109203x and their efficient conversion to the bioactive indolocarbazoles. Org. Biomol. Chem. 2006, 4, 3228-3234.
72. Routier, S.; Ayerbe, N.; Mérour, J. Y.; Coudert, G.; Bailly, C.; Pierré, A.; Pfeiffer, B.; Caignard, D.H.; Renard, P. Synthesis and biological evaluation of 7-azaindolocarbazoles. Tetrahedron 2002, 58, 6621-6630.
73. Popowycz, F.; Routier, S.; Joseph, B.; Merour, J-Y. Synthesis and reactivity of 7-azaindole (1H-pyrrolo[2,3-b]pyridine). Tetrahedron 2007, 63, 1031-1064.
74. Marminon, C.; Pierré, A.; Pfeiffer, B.; Pérez, V.; Léonce, S.; Joubert, A.; Bailly, C.; Renard, P.; Hickman, J.; Prudhomme, M. Synthesis and antiproliferative activities of 7-azarebeccamycin analogues bearing one 7-azaindole moiety. J. Med. Chem. 2003, 46, 609-622.
75. Messaoudi, S.; Anizon, F.; Pfeiffer, B.; Golsteyn, R.; Prudhomme, M. Synthesis of a staurosporine analogue possessing a 7-azaindole unit instead of an indole moiety. Tetrahedron Lett. 2004, 45, 4643-4647.
76. Messaoudi, S.; Anizon, F.; Pfeiffer, B.; Prudhomme, M. Synthesis of bridged aza-rebeccamycin analogues. Tetrahedron 2005, 61, 7304-7316.
77. Messaoudi, S.; Anizon, F.; Léonce, S.; Pierré, A.; Pfeiffer, B.; Prudhomme, M. Synthesis and cytotoxicities of 7-aza rebeccamycin analogues bearing various substituents on the sugar moiety, on the imide nitrogen and on the carbazole framework. Eur. J. Med. Chem. 2005, 40, 961-971.
78. Messaoudi, S.; Anizon, F.; Peixoto, P.; David-Cordonnier, M.H.; Golsteyn, R. M.; Léonce, S.; Pfeiffer, B.; Prudhomme, M. Synthesis and biological activities of 7-azarebeccamycin analogues bearing the sugar moiety on the nitrogen of the pyridine ring. Bioorg. Med. Chem. 2006, 14, 7551-7562.
79. Conchon, E.; Anizon, F.; Aboab, B.; Golsteyn, R. M.; Léonce, S.; Pfeiffer, B.; Prudhomme, M. Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3-diones, and 2-aminopyridazino[3,4-a]pyrrolo[3,4-c] carbazole-1,3,4,7-tetraone. Eur. J. Med. Chem. 2008, 43, 282-292.
80. Fabian, M. A.; Biggs III, W.H.; Treiber, D.K.; Atteridge, C.E.; Azimioara, M.D.; Bendetti, M.G.; Carter, T.A.; Ciceri, P.; Edeen, P.T.; Floyd, M.; Ford, J.M.; Galvin, M.; Gerlach, J.L.; Grotzfeld, R.M.; Herrgard, S.; Insko, D.E.; Insko, M.A.; Lai, A.G.; Lelias, R.M.; Mehta, S.A.; Milanov, Z.V.; Velasco, A.M.; Wodicka, L.M.; Patel, H.K.; Zarrinkar, P.P.; Lockhardt, D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
81. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I.; Edeen, P.T.; Faraoni, R.; Floyd, M.; Hunt, J.P.; Lockhardt, D.J.; Milanov, Z.V.; Morrison, M.J.; Pallares, G.; Patel, H.K.; Pritchard, S.; Wodicka, L.M.; Zarrinkar, P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127-132.